The convenience of skipping injections must be weighed against potentially variable absorption rates and the need for more precise timing around meals
Hims originally expanded its weight management business at the end of 2023, initially launching oral medication kits, followed by the introduction of custom-made GLP-1 therapies in May 2024
Healthcare professionals should regularly review nutritional status and consider referral to dietetic services for patients struggling to maintain adequate protein and overall nutritional intake during Ozempic therapy
While the main substance patent for semaglutide is expected to expire in 2026, other patents, especially those covering specific formulations, uses, and delivery devices, may extend protections into the 2030s, effectively delaying generic entry
Available from: Hashimoto E, Tokushige K, Ludwig J